Export financials
Gamida Cell Ltd. (GMDA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Gamida Cell Ltd. Financial Ratios 2021-2011 | GMDA
Annual Financial Ratios Gamida Cell Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -4.9 | -4.4 | -6.8 | - | - | - | - | - | - | - | |
EPS |
- | 1.7 | 1.2 | 10.5 | 27.6 | 32.9 | - | - | - | - | - |
EV (Enterprise Value) |
- | 283 M | 144 M | 359 M | 641 K | -9.84 M | - | - | - | - | - |
EBITDA per Share |
- | -1.43 | -1.37 | -1.34 | - | - | - | - | - | - | - |
EV/EBITDA |
- | -3.6 | -2.4 | -9.5 | - | - | - | - | - | - | - |
PEG |
- | -0.08 | 0.09 | -0.04 | - | - | - | - | - | - | - |
P/B |
- | 3.6 | 4.3 | 14.5 | - | - | - | - | - | - | - |
P/CF |
- | -5.8 | -3.7 | -12.8 | - | - | - | - | - | - | - |
ROE % |
- | -73.63 | -98.19 | -214.41 | - | - | - | - | - | - | - |
ROA % |
- | -46.76 | -49.95 | -81.23 | - | - | - | - | - | - | - |
ROCE % |
- | -46.52 | -84.08 | -57.55 | - | - | - | - | - | - | - |
Current Ratio |
- | 6.0 | 5.0 | 9.3 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Gamida Cell Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | 0.33 | 0.36 | - | - | 0.3 | 0.37 | - | - | - | -0.23 | - | - | - | 18.97 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.42 | - | - | - | -14.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
- | -42.72 | -85.45 | -118.67 | -75.95 | -100.30 | -81.94 | -68.91 | -44.55 | -44.55 | 8.81 | 58.02 | 58.02 | 29.01 | -301.30 | -660.61 | -660.61 | -330.31 | -330.31 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
- | -11.89 | -23.78 | -35.18 | -23.29 | -38.24 | -41.29 | -43.19 | -28.24 | -28.24 | -2.16 | 22.27 | 22.27 | 11.14 | -28.71 | -79.70 | -79.70 | -39.85 | -39.85 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | -16.36 | -32.71 | -46.42 | -30.07 | -47.83 | -49.24 | -48.42 | -30.65 | -30.65 | -37.42 | -49.06 | -49.06 | -24.53 | -60.34 | -71.61 | -71.61 | -35.81 | -35.81 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Gamida Cell Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Innate Pharma S.A.
IPHA
|
$ 0.87 | -7.57 % | $ 77.9 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 60.42 | -1.64 % | $ 11.6 B | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 0.75 | -9.23 % | $ 4.11 M | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 7.6 | -4.82 % | $ 220 M | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.38 | -5.66 % | $ 40.4 M | ||
|
Lipocine
LPCN
|
$ 1.47 | -2.33 % | $ 8.01 M | ||
|
Seres Therapeutics
MCRB
|
$ 1.25 | -6.02 % | $ 11.1 M | ||
|
Oramed Pharmaceuticals
ORMP
|
$ 3.58 | -2.98 % | $ 148 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 378.19 | -4.68 % | $ 8.48 B | ||
|
CEL-SCI Corporation
CVM
|
$ 1.2 | -18.37 % | $ 9.62 M | ||
|
Inventiva S.A.
IVA
|
$ 3.14 | -9.13 % | $ 188 M | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 7.98 | -1.97 % | $ 642 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 39.21 | 1.76 % | $ 44.9 B | ||
|
Eton Pharmaceuticals
ETON
|
$ 60.77 | -0.96 % | $ 1.64 B | ||
|
IDEAYA Biosciences
IDYA
|
$ 25.52 | -2.48 % | $ 2.26 B | ||
|
Protalix BioTherapeutics
PLX
|
$ 2.89 | -5.56 % | $ 227 M | ||
|
Lantern Pharma
LTRN
|
$ 0.25 | -13.67 % | $ 2.72 M | ||
|
Foghorn Therapeutics
FHTX
|
$ 1.71 | -3.93 % | $ 108 M | ||
|
Ocugen
OCGN
|
$ 0.77 | 4.74 % | $ 241 M | ||
|
Oncolytics Biotech
ONCY
|
$ 0.35 | -10.37 % | $ 33.6 M | ||
|
Minerva Neurosciences
NERV
|
$ 2.03 | -4.25 % | $ 17.2 M | ||
|
Neurocrine Biosciences
NBIX
|
$ 150.5 | -3.89 % | $ 15 B | ||
|
Nanobiotix S.A.
NBTX
|
$ 26.12 | -1.7 % | $ 1.25 T | ||
|
Prothena Corporation plc
PRTA
|
$ 8.12 | -3.33 % | $ 437 M | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.26 | -5.45 % | $ 207 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 6.99 | -2.85 % | $ 1.01 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.53 | -8.68 % | $ 555 M | ||
|
Moleculin Biotech
MBRX
|
$ 7.73 | -2.59 % | $ 9.16 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 21.79 | 1.66 % | $ 34.4 B | ||
|
Nurix Therapeutics
NRIX
|
$ 12.88 | -5.29 % | $ 1.12 B | ||
|
Nkarta
NKTX
|
$ 1.14 | 1.34 % | $ 84.3 M | ||
|
MacroGenics
MGNX
|
$ 1.97 | -0.76 % | $ 124 M | ||
|
Protagonist Therapeutics
PTGX
|
$ 121.72 | -2.2 % | $ 7.74 B | ||
|
Novo Nordisk A/S
NVO
|
$ 37.8 | -2.82 % | $ 168 B | ||
|
Marker Therapeutics
MRKR
|
$ 1.1 | -17.05 % | $ 16.8 M | ||
|
Arcus Biosciences
RCUS
|
$ 15.62 | -1.01 % | $ 1.68 B | ||
|
Replimune Group
REPL
|
$ 19.07 | -0.83 % | $ 1.77 B | ||
|
NextCure
NXTC
|
$ 6.62 | -2.43 % | $ 35.2 M | ||
|
Rocket Pharmaceuticals
RCKT
|
$ 1.95 | -7.82 % | $ 217 M | ||
|
PMV Pharmaceuticals
PMVP
|
$ 0.87 | -33.79 % | $ 45.7 M | ||
|
United Therapeutics Corporation
UTHR
|
$ 553.08 | -1.08 % | $ 24.5 B | ||
|
Olema Pharmaceuticals
OLMA
|
$ 7.0 | -2.1 % | $ 609 M | ||
|
Kymera Therapeutics
KYMR
|
$ 115.19 | -3.52 % | $ 9.73 B | ||
|
Oragenics
OGEN
|
$ 0.16 | -6.16 % | $ 345 K | ||
|
Ovid Therapeutics
OVID
|
$ 2.2 | -5.98 % | $ 286 M | ||
|
Passage Bio
PASG
|
$ 3.94 | 9.14 % | $ 12.6 M | ||
|
Vaxcyte
PCVX
|
$ 55.37 | -5.12 % | $ 7.54 B | ||
|
Relay Therapeutics
RLAY
|
$ 16.11 | 1.26 % | $ 2.76 B | ||
|
Precigen
PGEN
|
$ 4.21 | 1.08 % | $ 1.32 B |